Search This Blog

Showing posts with label Oncology. Show all posts
Showing posts with label Oncology. Show all posts

Osteosarcoma


The most common primary bone tumor affecting children and young adults. Boys between ages 13 and 16 years are at higher risk. In children, the tumor occurs most frequently at the metaphyses of long bones such as the distal femur, proximal tibia and proximal humerus
Constitutional symptoms such as fever, weight loss, and malaise are usually absent. On physical examination, the most important finding is a tender soft-tissue mass. Characteristics x-ray findings include a spiculated ''sunburst'' pattern and periosteal elevation known as Codman triangle.
Alkaline phosphatase and lactate dehydrogenase are elevated from turnover of damaged osteocytes; high levels may correlate with adverse prognosis. Increased ESR rate is a non-specific marker of inflammation.

Treatment :

includes tumor excision and chemotherapy

Radical abdominal hysterectomy (RAH)


  • Radical abdominal hysterectomy specimen with fetus in situ performed at 18 weeks of gestation for stage IB cervical cancer.

Carcinoma of Prostate

 Epidemiology
  •  Most common cancer in men
  •  Second most common cause of cancer death in men
  •  Incidence increases with age
  •  Highest rate in African Americans
Gross
  • ill-defined, firm, yellow mass
  • Commonly arises in the posterior aspect of the peripheral zone

Micro
  • Adenocarcinoma
  • Gleason grading system
Spread

1.Local spread
  • Tends to grow upwards to involve seminal vesicles, bladder neck, trigone, lower end of ureter.
2. Hematogenous
  • Bone esp, pelvic bone and lower lumber vertebrae.( osteoblastic)
  • Femoral head, rib cage and skull are other common sites.
3. Lymphatic
  • Commonly goes to the obturator and pelvic lymph nodes
TNM Staging

1. T1a, T1b, T1c: incidentally found tumor.
T1a : tumor involving less than 5% of the resected specimen
T1b: Tm involving greater than 5% of the resected specimen
        T1c: impalpable tumor found following a raised PSA.

2. T2a: suspicious nodule on rectal examination confined within prostate capsule involving one lobe.
T2b: involves both lobes

3. T3: extends beyond the capsule
T3a: U/L or B/L extension
T3b: seminal vesicle extension

4. T4: tm which is fixed or invading adjacent structures other than seminal vesicles- rectum or pelvic side wall


Clinical Presentation


  • Often clinically silent
  • May present with lower back pain secondary to metastasis
  • Advanced localized disease may present with urinary tract obstruction or UTIs
Investigations

  • Digital rectal exam (induration)
  • Serum PSA levels
  • Transrectal U/S and biopsy
  • Alkaline phosphatase elevated with metastasis
  • Bone scan
Treatment

Local disease (T1 and T2):
 prostatectomy and/or external beam radiation
  • Metastatic disease (T3 and T4): B/L Orchidectomy
  • Estrogens or androgen receptor blockade (flutamide or leuprolide)
  • Monitor with PSA levels

Proto-oncogenes (tumor promoters) versus Anti-oncogenes (tumor suppressors)

Abnormal growth of neoplastic cells can arise secondary to mutation of either proto-oncogenes or anti oncogenes. Proto-oncogenes stimulate cell proliferation. Overexpression or amplification of a proto-oncogene leads to increased cellular proliferation and neoplastic growth. Anti-oncogenes, in contrast, are tumor suppressors in that they inhibit cellular proliferation. Inactivation of anti-oncogenes contributes to tumor development. 


Acute Myeloid Leukemia

Failure of cell maturation
Common age group. is 15 to 45 yrs.

Etiology

Heredity
    trisomy 21  (Down syndrome),  Inherited diseases with defective DNA repair, e.g., Fanconi anemia, Bloom syndrome, ataxia telangiectasia

Radiation - ionizing

Chemical and other occupational exposures
  •    Exposure to benzene, 
  •    Smoking and exposure to petroleum products, paint, herbicides, and pesticides, 

Drugs
  •     Alkylating agents
  •     Chloramphenicol, phenylbutazone, and, less commonly, chloroquine


French-American-British (FAB) Classification

M0: Minimally differentiated leukemia,5%
M1:Myeloblastic leukemia without     maturation,20%
M2: Myeloblastic leukemia with maturation,30%
M3: Hypergranular promyelocytic ,10%
M4: Myelomonocytic leukemia, 20%
M4Eo: Variant: Increase in abnormal marrow eosinophils
M5: Monocytic leukemia,10%
M6: Erythroleukemia (DiGuglielmo's disease), 4%
M7: Megakaryoblastic leukemia,1%

Clinical Presentation

Symptoms

Consequence of anemia, leukocytosis, leukopenia or leukocyte dysfunction, or thrombocytopenia. 3 months symptoms
fatigue or weakness, anorexia, weight loss, fever, Signs of abnormal hemostasis (bleeding, easy bruising) 
bone pain, lymphadenopathy, nonspecific cough, headache, or diaphoresis 

a mass lesion located in the soft tissues, breast, uterus, ovary, cranial or spinal dura, gastrointestinal tract, lung, mediastinum, prostate, bone, or other organs. 
The mass lesion represents a tumor of leukemic cells and is called a granulocytic sarcoma, or chloroma. 

Physical Findings

Fever, splenomegaly, hepatomegaly, lymphadenopathy, sternal tenderness, evidence of infection and hemorrhage  
GI bleeding, intrapulmonary hemorrhage, or intracranial hemorrhage  
Retinal hemorrhages, Infiltration of gingivae, skin, soft tissues, or the meninges with leukemic blasts at diagnosis is characteristic of the monocytic subtypes and those with 11q23 chromosomal abnormalities.  

Hematologic Findings

Severe  anemia : normocytic  normochromic
Decreased erythropoiesis often results in a reduced reticulocyte count,accelerated destruction of RBC. 
Active blood loss also contributes to the anemia.

Leukocytosis between 10,000 to 500,000 per cmm.
Leukemic cells in the blood 

Hyperuricemia
renal precipitation of uric acid and the nephropathy 
renal tubular dysfunction

Bone marrow findings

blasts are >20%
cytoplasm often contains primary (nonspecific) granules, and the nucleus shows fine, lacy chromatin with one or more nucleoli characteristic of immature cells.
Abnormal rod-shaped granules called Auer rods


Prognostic Factors

Advancing age is associated with a poorer prognosis,
Patients with t(15;17) have a very good prognosis (approximately 85% cured),

 with t(8;21) and inv(16) a good prognosis (approximately 50% cured

Treatment

Remission induction
    Standard therapy includes a 7-day continuous infusion of cytarabine and a 3-day course of daunorubicin or idarubicin with or without 3 days of etoposide.


Supportive Care

G-CSF and granulocyte-macrophage colony-stimulating factor (GM-CSF)
Platelet transfusions to maintain a platelet count >20,000/L
RBC transfusions to maintain hemoglobin level >8 g/dL
Prophylactic antibiotics for infection contrl
 Oral nystatin or clotrimazole  to prevent localized candidiasis, acyclovir prophylaxis
Allopurinol – to prevent from tumor lysis syndrome
Consolidation
Patients who achieve complete remission undergo postremission consolidation therapy, including sequential courses of high-dose cytarabine, stem cell transplant (SCT),
Maintenance
prednisolone, vincristine, methotrexate and mercaptopurine

Patients with APL usually receive tretinoin together with anthracycline chemotherapy for remission induction and then consolidation chemotherapy (daunorubicin) followed by maintenance tretinoin, with or without chemotherapy.

Treatment of relapse
Once relapse has occurred, AML is generally curable only by SCT.

CHRONIC MYELOID LEUKEMIA


A clonal expansion of a hematopoietic stem cell possessing a reciprocal translocation between chromosomes 9 and 22. 

This translocation results in the head-to-tail fusion of the breakpoint cluster region (BCR) gene on chromosome 22 with the ABL gene located on chromosome 9. 

Age gp. – 30 to 60 years


Etiology
  • No evidence of cytotoxic drugs or a viral etiology. 
  • Cigarette smoking accelerated the progression to blast crisis 
  • Atomic bomb survivors had an increased incidence;  only large doses of radiation can induce CML.
Three phases
  • Chronic phase
  • Accelerated  phase
  • Blast crisis phase

Clinical Presentation


Signs and Symptoms
 
Fatigue, malaise, and weight loss or  splenic enlargement and symptoms, such as early satiety and left               upper quadrant pain or mass.
 
Granulocyte or platelet dysfunction, such as infections, thrombosis, or bleeding.
 
Severe leukocytosis or thrombosis such as vasoocclusive disease, cerebrovascular accidents, myocardial infarction, venous thrombosis, priapism, visual disturbances, and pulmonary insufficiency.

Unexplained fever, significant weight loss, increasing dose requirement of the drugs controlling the disease, bone and joint pain, bleeding, thrombosis, and infections suggest transformation into accelerated or blastic phases.


Physical Findings

Minimal to moderate splenomegaly; mild hepatomegaly
Lymphadenopathy and myeloid sarcomas are unusual except late in the course of the disease; poor prognosis


Hematologic Findings in chronic phase

Elevated white blood cell counts (WBCs), with increases in both immature and mature granulocytes, are present at diagnosis; 16,000 to 200,00/cmm
Usually less than 5% circulating blasts
Platelet counts elevated or decreased, a mild degree of normocytic normochromic anemia .

Leukocyte alkaline phosphatase is low in CML cells.
Histamine production secondary to basophila is increased in later stages, causing pruritus, diarrhea, and flushing.

Bone marrow cellularity is increased, with an increased myeloid to erythroid ratio. The marrow blast percentage is generally normal to less than 5%

Marrow or blood basophilia, eosinophilia, and monocytosis

Disease acceleration: the development of increasing degrees of anemia or blood or marrow blasts between 10 and 20%, blood or marrow basophils 20%, or platelet count less than 100,000/L.
Blast crisis: Acute leukemia, with blood or marrow blasts 20%.

Chromosomal Findings

The cytogenetic hallmark of CML, is the t(9;22)

 Recognized by the presence of a shortened chromosome 22 (22q-), designated as the Philadelphia chromosome, that arises from the reciprocal t(9;22). Some patients may have complex translocations (designated as variant translocations) involving three, four, or five chromosomes (usually including chromosomes 9 and 22).

Treatment

The goal is complete hematologic, and cytogenetic remission, cure
Complete hematologic remission, WBC less than 10,000/mL, normal blood morphology, hemoglobin and platelet counts, and disappearance of splenomegaly.
Complete cytogenetic remission, no bone marrow metaphases with t(9;22).

Rapid lowering of WBCs, reduction of symptoms,   and reversal of symptomatic splenomegaly.
Imatinib mesylate tyrosine kinase inhibitorinduces apoptosis in cells expressing Bcr/Abl.

Hydroxyurea induces rapid disease control
Busulphan, an alkylating agent  acts on early progenitor
Interferon – if all other options have failed; mechanism is unknown

Autologous SCT

Intensive leukapheresis may control the blood counts in chronic-phase CML
 leukostasis-related complications such as pulmonary failure or cerebrovascular accidents,
Splenectomy for symptomatic relief of painful splenomegaly unresponsive to imatinib or chemotherapy, or for significant anemia or thrombocytopenia associated with hypersplenism. Splenic radiation

Treatment of Blast Crisis
 Only 52% of patients treated with imatinib achieved hematologic remission (21% complete hematologic remission), and the median overall survival was 6.6 months.
 allogeneic SCT with chemotherapy

Allogeneic SCT

The Patient
The Donor
Sex mismatch has an adverse effect on transplantation, with worse outcome associated with a female donor and male recipient. This has been attributed to GVHD against the male histocompatibility Y antigen.

Post-transplantation Treatment

BCR/ABL transcript levels have served as early predictors for hematologic relapse following transplantation.
Imatinib can control CML that has recurred after allogeneic SCT.

Acute lymphoblastic leukemia (ALL)

Clonal proliferation and accumulation of blast cells from lymphoid series in blood, bone marrow and other organs

Disorder  originates in single B or T lymphocyte progenitor 

B cell type – 80%     T cell type – 20%
Common age group – 5 to 15 yrs
Etiology  - unknown 

Acute leukemias - clinical features

1. Bleeding
2. Fever/infection
3. Fatiguability and pallor
4. Hepatomegaly
5. Splenomegaly
6. Lymphadenopathy
7. CNS involvement
8. Testicular involvement in males


Acute leukemias - laboratory findings 

1. Blood examination - anemia, - thrombocytopenia, - variable leukocyte count, usually increased from 10,000 to 500,000/cmm - blood morphology: presence of blast cells 

2. Bone marrow morphology - presence of blast cells (>20%) - suppression of normal hematopoiesis
3. Cytochemical stains
4. Immunophenotyping
5. Cytogenetics

Immune phenotyping
Cytogenetics
Morphologic subtypes of acute lymphoblastic leukemias  (FAB classification)

Subtype           Morphology       Occurrence (%)
L1   Small round blasts              75
clumped chromatin
L2 Pleomorphic larger blasts     20
clefted nuclei, fine chromatin
L3 Large blasts, nucleoli,       5

vacuolated cytoplasm

Chromosomal/molecular abnormalities with prognostic significance in ALL

Better prognosis
- normal karyotype
- hyperdiploidy
Poor prognosis
- t (8; 14)
- t (4; 11)
Very poor prognosis
- t (9; 22); BCR/ABL (+)


 Treatment strategy in ALL

Remission induction therapy in ALL

1. Antineoplastic treatment
a.Drugs: L-asparaginase, Daunorubicin, Prednisolone, Vincristine
    b/Treatment duration: 4-8 weeks
c/ No of courses: 1- 2
2. CNS prophylaxis – Methotrexate (intrathecal)
3. Supportive care

4. Treatment of complications

Consolidation

Drugs – Etoposide, cytarabine, and Daunorubicn, Methotrexate(I.v.)
+/-

Stem Cell transplantation

Maintenance of remission


  • Prednisolone, Vincristine, Mercaptopurine and Methotrexate (oral)
  • May need to be continued for 2-3 years



Treatment results in ALL 

Adults
Complete remission  (CR) 80-85%
Leukemia-free survival (LFS)            30-40%

Children
Complete remission (CR) 95-99%
Leukemia-free survival (LFS)            70-80%

Colon polyps types description and their progression to malignancy



  • Type : Hyperplastic polyp 


Description
Sawtooth glandular epithelium with proliferation of globet and columnar epithelial cells

Progression to Malignancy
No
  • Type: Tubular adenoma


Description
Pedunculated

Progression to Malignancy
Low (4%)




  • Type : Tubulovillous adenoma


Description
Combines both

Progression to Malignancy
Intermediated



  • Type : Villous adenoma


Description
Sessile

Progression to Malignancy
High (30%)


  • Type : Famililal Adenomatous Polyposis


Description
Autosomal Dominant Thousands of Colonic adenomatous polyps

Progression to Malignancy
100% (by 40 year)




  • Type : Gardner syndrome


Description
Autosomal Dominant Associated with desmoid tumors

Progression to Malignancy
~ 100%




  • Type : Turcot Syndrome


Description
Associated with CNS tumors(gliomas)

Progression to Malignancy
Highly


  • Type : Peutz-Jeghers Syndrome


Description
Autosomal Dominant Hamartomas. Melanin Pigmentation of the buccal mucosa

Progression to Malignancy
No



Figure : Colonic adenocarcinoma of cecum


  • Colon Cancer 


HNPCC (lynch Syndrome)

  • Autosomal Dominant
  • Mutation of DNA nucleotide mismatch repair gene
  • Increased risk of endometrial and ovarian carcinoma



Genetic conditions (Germline genetic disease) Involved chromosomal sites



  • 5q21 is the location of the APC mutation that predisposes for FAP.



  • 11p13 is the site of the WT-1 tumor gene



  • 13q14 is the site of the RB retinoblastoma gene.



  • 17q11 is the site of the NF-1 neurofibromatosis gene,



  • 22q12 is the site of the NF-2 neurofibromatosis gene.

Neoplasia : Differentiation and anaplasia

Differentiation and anaplasia:
Apply to the parenchymal cells of neoplasms

Differentiation



Extent to which parenchymal cells resemble comparable normal cells, both morphologically and functionally
Well-differentiated tumors- cells resemble the mature normal cells of tissue of origin; better retains the fx of normal cells
Evolves from maturation or specialization of undifferentiated cells as they proliferate
Poorly-differentiated tumors – primitive-appearing, unspecialized cells
Does retain fx of normal cell; may acquire other fx’s such as elaboration of fetal ptns or ectopic hormone production
Derives from proliferation w/out maturation
Benign tumors usually well-differentiated
Malignant tumors usually range from anaplastic to well-differentiated

Anaplasia

Lack of differentiation
Example of anaplastic tumors = malignant neoplasms composed of undifferentiated cells
More rapidly growing and the more anaplastic a tumor, the less likely it is that there will be specialized functional activity

Morphology of Anaplasia:

Pleomorphism – variation in size and shape of both cell and nuclei
Hyperchromatic nuclei; nuclei contain an overabundance of DNA
Nuclei are too large for the cell
Nuclear to cytoplasmic ratio may reach 1:1 instead of normal 1:4 or 1:6
Chromatin is often coarsely clumped and distributed along the nuclear mbr
Usually see large nucleoli
High proliferative activity
Large numbers of mitoses
Atypical, bizarre mitotic figures sometimes w/ tripolar, quadripolar, or multipolar spindles
Tumor giant cells
Some possess only a single huge polymorphic nucleus, others w/ two or more nuclei
Loss of normal polarity; grow in sheets or large masses tumors in an anarchic, disorganized fashion
Vascular stroma is often scant; large central areas may undergo necrosis


Variations in cell growth and differentiation: normal and abnormal.

Increased growth.

Increased growth occurs in a tissue or organ due to increased functional demand. It can be the result of hyperplasia, hypertrophy or a combination of both. Stimuli for increased growth include hormones, growth factors and work against resistance.
Hyperplasia is an increase in cell number by cell division, often leading to an increase in the size of an organ.
Hypertrophy is an increase in cell size without cell division, usually leading to an increase in the size of an organ.
Both hyperplasia and hypertrophy can be physiological or pathological.

Some examples of physiological hyperplasia

The breast undergoes hyperplasia during puberty, pregnancy, and lactation, stimulated by hormones such as oestrogens, progesterone and prolactin.
Red cell precursors in the bone marrow undergo hyperplasia at high altitude, stimulated by erythropoietin, which has been evoked by hypoxia.
The thyroid undergoes hyperplasia in puberty and pregnancy, stimulated by increased metabolic demand.

Some examples of physiological hypertrophy

Skeletal muscle undergoes hypertrophy stimulated by increased muscle activity on exercise.
Cardiac muscle undergoes hypertrophy stimulated by sustained outflow increase in athletes.
Myometrium undergoes hypertrophy in pregnancy stimulated by oestrogens

Some examples of pathological hyperplasia

The prostate gland undergoes hyperplasia, stimulated by oestrogen.
The adrenal cortex undergoes hyperplasia (Cushing’s syndrome) stimulated by ACTH produced by pituitary, lung or other tumours.
The thyroid gland undergoes hyperplasia in Graves’ disease, stimulated by Thyroid-stimulating autoantibody.
The parathyroid gland undergoes hyperplasia stimulated by hypercalcaemia.
The endometrium undergoes hyperplasia stimulated by oestrogen.
Myointimal cells undergo hyperplasia in atheromatous plaques stimulated by Platelet Derived Growth Factor.
Keratinocytes in skin undergo hyperplasia in psoriasis, stimulated by cytokines released in an immune response.

Some examples of pathological hypertrophy

Cardiac muscle of the left ventricle undergoes hypertrophy because of increased outflow pressure eg systemic hypertension, aortic valve disease
Cardiac muscle of the right ventricle undergoes hypertrophy because of increased outflow pressure eg pulmonary hypertension, pulmonary valve disease.
Arterial smooth muscle undergoes hypertrophy in hypertension.
Decreased size of tissue or organ
This can occur in a tissue or organ due to developmental failure, or to reduction in size of a previously normal organ. This is atrophy.
Atrophy is a decrease in cell size and/or number in a previously normal tissue or organ. Decrease in cell number is mediated by apoptosis; decrease in cell size by a reduction in cell growth. Atrophy can be physiological or pathological.

Some examples of physiological atrophy

In the embryo & fetus, the notochord and branchial clefts undergo atrophy.
In the neonate, the umbilical vessels and ductus arteriosus undergo atrophy.
In early adulthood, the thymus undergoes atrophy.
In old age the uterus, testes, brain and bone all atrophy.

Some examples of pathological atrophy

Loss of function causes muscle atrophy and osteoporosis in immobilisation or weightlessness.
Loss of innervation causes muscle atrophy in nerve transection or poliomyelitis.
Loss of blood supply causes skin atrophy or bedsores in peripheral vascular disease or excess pressure.
Severe malnutrition causes atrophy in many tissues.
Loss of hormonal stimulation causes atrophy of adrenal cortex, thyroid, and gonads in hypopituitarism.
Excess hormones can cause atrophy: excess corticosteroids cause skin atrophy.

Abnormal differentiation
When mature tissues grow and differentiate abnormally, they can undergo metaplasia, dysplasia or both.

Metaplasia

Is defined as the transformation of one fully differentiated cell type into another.
Is an adaptive response to environmental stress, usually chronic irritation or inflammation; metaplastic tissues are better able to withstand the adverse environmental changes than are normal tissues
Is caused by activation and/or repression of groups of genes involved in the maintenance of cellular differentiation
There is no intrinsic gene defect (as there is in neoplasia), therefore metaplasia is reversible.
But, metaplastic tissues are more genetically unstable than their normal counterparts, so they may undergo further transformation to dysplasia and neoplasia
Can affect epithelial or connective tissue cells

Epithelial metaplasia can be:

Squamous: other epithelia transform to squamous epithelium.
Glandular: other epithelia transform to glandular epithelium.

Some examples of Squamous metaplasia are:

Ciliated pseudostratified columnar epithelium of respiratory tract; due to smoking, bronchiectasis, or chronic bronchitis.
Simple columnar epithelium of endocervix; due to changes of pH, injury, inflammation.
Transitional cell epithelium of bladder; due to Schistosomal infection or bladder calculi.

Some examples of Glandular metaplasia are:

Stratified squamous epithelium of oesophagus transforms to simple columnar epithelium due to gastro-oesophageal reflux: Barrett’s oesophagus.
Simple columnar epithelium of stomach transforms to intestinal epithelium, in chronic gastritis due to Helicobacter pylori

Mesenchymal metaplasia is much less common than epithelial metaplasia. There are three main types:

Osseous metaplasia – in old scars such as tuberculous scars in the lungs, in atheromatous plaques and in chronically damaged muscle
Chondroid metaplasia – in similar conditions to osseous metaplasia
Myeloid metaplasia (also known as extramedullary haemopoiesis) – in the spleen, liver and lymph nodes in patients with myeloproliferative diseases

Dysplasia refers to cells of abnormal phenotype that are not yet neoplastic, but are predisposed to be.

Encountered primarily in the epitheli
It is a premalignant process.
It is often preceded by metaplasia.
It is usually irreversible.
There is disordered maturation: the phenotype of the abnormal cells approaches that of malignant cells. Loss in uniformity of the individual cells as well as a loss in their architectural orientation. It is characterised by increased cell division, atypical cell morphology and lack of differentiation.
Considerable architectural anarchy
Considerable pleomorphism
Hyperchromatic nuclei
Nuclei are too large for cell
Increase numbers of mitotic figures, but conform to normal patterns; may appear in abnormal location w/in the epithelium

Examples include:

in str sq epithelium, mitoses are not confined to basal layers, may occur in surface cells.
Colonic epithelial dysplasia in longstanding ulcerative colitis.
Cervical Intraepithelial Neoplasia (CIN).
Glandular dysplasia in Barrett’s oesophagus
Paget’s disease of bone.

Carcinoma in situ

When dysplastic changes are marked and involve the entire thickness of the epithelium
Epithelial dysplasia almost invariably comes before the appearance of cancer
Dysplasia does not necessarily progress to cancer.

Examples of non-random chromosomal abnormalities in neoplastic diseases

Exchange of genetic material  between  two  genes, leading to the development of novel fusion gene which acts as an oncogene.

Epidemiology of Cancer

Epidemiology of Cancer:
  • Over last 50 yrs, the overall cancer death rate has significantly incr for men; for women, it has fallen slightly
  • Increase in men is due to lung cancer
  • Improvement for women is due to decline in death rates from cancers of uterus, stomach, liver, and carcinoma of the cervix
  • Carcinoma of the lung has incr in both sexes; beginning to decline in men, but still incr in women
  • Carcinomas of breast are 2.5X more frequent than carcinomas of lung, but lung cancer is leading cause of cancer deaths in women
  • Decrease in death from stomach and liver carcinomas – perhaps due to decr in dietary carcinogens
Cancer incidence and cancer death for men:
Cancer incidence and cancer deaths for women:
Geographic and Environmental Factors:
  • Much of geographic differences are consequences of environmental influences
  • Rates of cancer for immigrants comes closer to US rates of cancer with each succeeding generation
Environmental Factors:
  1. UV rays
  2. Asbestos, vinyl chloride, 2-naphthylamine 
  • Persons more than 25% overweight have a higher death rate from cancer
  • Alcohol – incr risk for carcinomas of oropharynx, larynx, esophagus, and liver
  • Smoking – incr risk for cancer of mouth, pharynx, larynx, esophagus, pancreas, bladder, and lung dz
  • Smoking is single most important environmental factor contributing to premature death in the US
  • Alcohol and tobacco together – incr risk of cancers in upper aerodigestive tract
  • Risk of cervical cancer is linked to age at first intercourse and the number of sex partners
Age:
  • Each age group has its own predilection to certain forms of cancer
  • Striking incr in mortality from cancer in 55-74 y/o
  • Under 15 y/o:
  • Cancer accounts for about 10% of deaths in this group
  • Most common is acute leukemia and neoplasms of the CNS
Heredity:
  • For a large number of cancers, there are environmental influences and hereditary predisposition’s
Inherited Cancer Syndromes – inheritance of a single mutant gene greatly incr risk of developing a tumor
  • Tumors involve specific sites and tissues
  • Tumors w/in this group are often associated w/ a specific marker phenotype
  • Both incomplete penetrance and variable expressitivity are noted
Familial Cancers
  • Almost all sporadic cancers have been reported to occur in familial forms
  • Early age at onset, tumors arising in two or more close relative of index case, and sometimes multiple or bilateral tumors
  • Not associated w/ specific marker phenotypes

Autosomal Recessive Syndromes of Defective DNA Repair:
  • Example is xeroderma pigmentosa

Autosomal Dominant Neoplasia Syndromes
RB, retinoblastoma; FAP, familial adenomatous polyposis; APC, adenomatous polyposis coli; MEN, multiple endocrine neoplasia; RET, rearranged during  transfection; VHL, von Hippel-Lindau.

Defective DNA Repair Syndromes

  • ATM, ataxia-telangiectasia mutated.
  • *Ataxia-telangiectasia is also associated with cerebellar ataxia.




Acquired Preneoplastic Disorders:
  • A premalignant lesion is an identifiable local abnormality associated with an increased risk of a malignant tumour developing at that site. 
  • In the great majority of cases, no malignant neoplasms emerge
  • Certain forms of benign neoplasia also constitute precancerous conditions
  • Example – villous adenoma of the colon
  • Most benign neoplasms do not become cancerous
Precancerous (Premalignant) Lesions.

Mechanisms of Invasion and Metastases

Local Invasion:
  • Almost all benign tumors grow as cohesive expansile masses
  • Remain localized to their site of origin
  • Do not have the capacity to infiltrate, invade, or metastasize to distant sites
  • Usually have rim of fibrous capsule that separates them from host tissue
  • Rim is composed of stroma of the native tissues as its parenchymal cells atrophy under the pressure of expanding tumor
  • Tends to be contained as a discrete, readily palpable, and easily movable mass
  • Some benign tumors can be encapsulated (example = hemangiomas)
  • The growth of malignant tumors is accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue
  • Poorly separated from surrounding normal tissue
  • Slowly expanding malignant tumors may develop an apparently enclosing fibrous capsule; capsule has breaks along its margin
  • Invasiveness is one of most reliable features (next to metastases) to differentiates malignant from benign tumors
  • Carcinoma in situ – displays the cytologic features of malignancy w/out invasion of the basement membrane
  • Example = carcinoma of the uterine cervix
  • Can be considered one step removed from invasive cancer
  • In time, most become invasive

Example of Disturbance of Growth:

  • Progression in cervix from normal squamous epithelium to squamous cell carcinoma in situ
  • Mild dysplasia is present when abnormal organization and cellular atypia is confined to the lower one third of the epithel layer
  • Moderate dysplasia – 1/3 to 2/3 of epithelium is involved
  • Severe dysplasia – indistinguishable from CIS since the full thickness of the epithelium is involved
  • In each of these situations the basement membrane is intact
  • Abnormal process is confined to the epith layer
Continuum:
  • Progression of cellular dysplasia to carcinoma-in-situ- to locally invasive carcinoma followed by metastases
Metastases:
  • Tumor implants discontinuous with the primary tumor
  • Unequivocally marks a tumor as malignant b/c benign neoplasms do not metastasize
  •  With few exceptions, all cancers can metastasize
  •  Exceptions are gliomas and basal cell carcinomas of the skin – both are highly invasive but rarely metastasize
  • More aggressive, more rapidly growing, and the larger the primary neoplasm, the greater the likelihood that it will metastasize
  • Strongly reduces the possibility of cure
  • About 30% of newly dx pts w/ solid tumors have metastases

Mechanisms of Invasion and Metastases:
1.      Clonal Expansion, growth, diversification, and angiogenesis
2.      Metastatic subclone adheres to and invades basement membrane
3.      Passes t/ ECM
4.      Intravasation
5.      Interaction w/ host lymphoid cells
6.      Tumor cell embolus
7.      Adhesion to basement membrane
8.      Extravasation
9.      Metastatic deposit
10.  Angiogenesis
11.  Growth

Factors in Invasion and Metastases:



Pathways of Spread:
1.      Direct seeding of body cavities or surfaces
2.      Lymphatic spread
3.      Hematogenous spread

Direct seeding of body cavities or surfaces:

  • May occur whenever a malignant neoplasm penetrates into an open field
  • Most often is the peritoneal cavity, but also can be any other cavity
  • Esp common of carcinomas arising from ovaries à coats all peritoneal surfaces w/ cancerous glaze
  • Pseudomyxoma peritonei – mucus secreting ovary and appendiceal carcinomas fill peritoneal cavity w/ gelatinous neoplastic mass

Lymphatic Spread:

  • Most common p’way for initial dissemination of carcinomas
  • Sarcomas also use this p’way
  • Pattern of lymph node involvement follows the natural routes of drainage
  • Local lymph nodes may be bypassed b/c of venous-lymphatic anastomoses, or b/c inflamm or radiation has obliterated channels
  • Regional nodes serve as effective barriers to further dissemination, at least for a while
  • Tumor-specific immune response may participate
  • Enlargement of lymph nodes may be caused by:
1.      Spread and growth of cancer cells
2.      Reactive hyperplasia

  • Nodal enlargement in proximity to a cancer does not necessarily mean dissemination of the primary lesion

Hematogenous Spread:
  1. Typical of sarcomas, but also used by carcinoma
  2.  Arteries have thicker walls, are less readily penetrated than are veins
  3. Arterial spread may occur when tumor cells pass t/ pulmonary capillary beds or pulmonary arteriovenous shunts, or pulmonary metastases give rise to tumor emboli
  4. Venous invasion: blood-borne cells follow the venous flow, draining the site of the neoplasm
  5.  Liver and lungs are most frequently involved secondarily in venous dissemination
  • All portal area drainage flows to liver
  • All caval blood flows to lungs

Grading and staging of cancer

Grading criteria
  • Degree of differentiation (e.g., low, intermediate, or high grade)
  • Nuclear features, invasiveness
Staging criteria
  •  Most important prognostic factor
TNM system
  • Universal system
  • Progresses from the least to the most important prognostic factor
  • T refers to tumor size
  •  ≥2cm correlates with metastatic ability.
  • N refers to whether lymph nodes are involved.
  •  M refers to extranodal metastases (e.g., liver, lung).
Other systems
  • For individual cancers
  •  Duke staging for intestinal cancer

Cell Markers and Genetic Abnormalities for Hodgkin and Non-Hodgkin Lymphomas


HODGKIN LYMPHOMA

Hodgkin lymphoma with a Reed-Sternberg cell
In the center of the photomicrograph is a classic Reed-Sternberg cell,a binucleate cell with large “owl’s eyes” eosinophilic nucleoli.

Hodgkin lymphoma, nodular sclerosis variant
Note the nodules of lymphocytes and other hematopoietic cells divided by broad fibrous septae.

Hodgkin lymphoma, mixed cellularity variant
Note the Reed-Sternberg cell (arrowhead). The other cell types in this image are reactive (only the Reed-Sternberg cell is neoplastic) and include neutrophils, lymphocytes, and, prominently in this image,eosinophils.

NON-HODGKIN LYMPHOMA
Spleen, non-Hodgkin lymphoma. This spleen exhibits uniform multicentric involvement of the white pulp by a malignant lymphoma. These changes contribute to generalized splenomegaly.

Follicular lymphoma

This lymph node exhibits the characteristic low power features of follicular lymphoma, tightly packed lymphoid follicles of approximately equal size.
Follicular lymphoma involves this hilar lymph node. The black material (arrow) represents normal lymphoid parenchyma with anthracotic pigment displaced 
to one side by the expanding tan lymphomatous process.


Diffuse large B-cell lymphoma
The photomicrograph shows a sheet of monotonous large neoplastic cells with prominent nucleoli.

Burkitt lymphoma
This photomicrograph illustrates the characteristic low power features of Burkitt lymphoma, a sheet of neoplastic cells interspersed with punctate clearings (“starry sky pattern”). The punctate clearings are macrophages engulfing cellular debris. Burkitt lymphoma is an aggressive rapidly growingneoplasm with abundant cellular turnover, hence the presence of the macrophages


Hairy cell leukemia
In the upper left corner is a single neoplastic lymphoid cell. Note the fine hair-like projections from its surface.


General Category Specific Name of Genetic Abnormality of Lymphoma Lymphoma Cell Markers (if associated with one)

Hodgkin lymphoma 


  • NS-HL CD 15, 30+ EBV
  • MC-HL CD 15, 30+ EBV+
  • LP-HL CD 20, EMA + CD 15, 30


Non-Hodgkin lymphoma 


  • Follicular lymphoma CD 19,20, and 10+ t(14;18)–bcl-2 surface Ig, bcl-2+ 3q27 abnormalities



  • Diffuse large B-cell CD 19,20, and 79a+ t(14;18)–bcl-2 lymphoma Surface Ig+ 3q27 abnormalities



  • Burkitt lymphoma CD 10, 19 and 20+ t(8;14)–MYC Bcl-6 and surface Ig+



  • Precursor T-cell lymphoblastic Tdt, CD 2 and 7+ Abnormalities of TAL1 leukemia/lymphoma



  • Mantle cell lymphoma CD 19,20 and 5+ t(11;14)–cyclin D1 Surface Ig+ CD23



  • MALToma CD19, 20 t(1;14)–bcl-10 t(11;18)



  • Hairy cell leukemia CD 19, 20, 11c and 103 TRAP+


NS-HL, nodular sclerosis Hodgkin lymphoma; EBV, Epstein-Barr virus; EMA, epithelial membrane antigen; MC-HL, mixed cellularity Hodgkin lymphoma; LPHL,
lymphocyte predominant Hodgkin lymphoma; TRAP, tartrate-resistant acid phosphatase.

ENDOMETRIAL CARCINOMA


Background

Most common gynaecological carcinoma in
developed countries
Japan and Asia have 5 times lower incidence

Most cases are post-menopausal
< 5% under age of 40 ( hyperestrogenic )
At diagnosis 75% have Stage 1 disease
OBESITY strong link as peripheral conversion to Estrone
SHBG(sex hormone binding globulin) decrease with an increase in FREE estrogen for uptake in target tissues

Lifetime risk: 1.1%
Lifetime risk of dying: 0.4%
5-year survival rates are considered to be
good at around 75%

The prognosis is generally good because the majority
of patients are diagnosed in an early stage

Role of hormones (estrogen)

Estrogen dependent disease
Prolonged exposure without the balancing effects of progesterone

Conditions of Estrogen excess

Early Menarche and Late Menopause

Associated with more estrogen exposure

Estrogen Replacement Therapy

Place women at high risk
Risk reduced when + progesterone

Tamoxifen

Anti-estrogenic drug for breast cancer
Side effect
Induces non-cancerous uterine tumors
Some may develop into endometrial cancer
Long term use => endometrial cancer
Only 1 in 500 develop endometrial cancer

Reduced Risk

Oral Contraceptives

Combined OC => 50% reduced rate
Actual reduction number small because uncommon in women of child bearing age
Long term offers protection
Reduced risk presumably => progesterone

Physical exercise and fruit vegetables diet


Endometrial Carcinoma: aetiology

Hyperoestrogenic states

Age - mainly 60-70 years (late menopause)
Parity - nulliparity, relative infertility
Metabolic disorders [Cancer Triad]
Obesity, Diabetes, Hypertension
Ovarian tumours
granulosa cell tumour, PCOD
unopposed Exogenous oestrogens [HRT]

other conditions
leiomyomas; adenomyosis, endometriosis, breast Ca

Risk factors
  • Usually in postmenopausal women
  • Unapposed estrogen stimulation
  • Preceded by endometrial hyperplasia
  • Simple hyperplasia

Adenomatous hyperplasia

Cellular Atypia

Clinical Features

Abnormal bleeding
mainly postmenopausal
intermenstrual or pre-menstrual
menorrhagia

Lower abdominal pain
abnormal vaginal discharge / pyometra

Endometrial Carcinoma


Diagnosis

Endometrial sampling
Dilation and curettage / Endometrial aspiration

Image
TVS / CT scan / MRI

Standard
Hysteroscopy + targeted biopsy

Tumor marker
Ca 125 / 199

Cystoscope / Proctoscope

Prevention

Early detection is best prevention
Treating precancerous hyperplasia
Hormones (progestin)
Hysterectomy
10 ~ 30% untreated develop into cancer

Histology/ grade

90% endometrial adenocarcinoma
Arise from the epithelium

Tumor grading
Grade 1
Well differentiated
Grade 2
Moderately differentiated with solid component
Grade 3
Poorly differentiated with solid sheets of tumor

Rare cell types

10% rare cell types
Papillary serous carcinoma
Clear cell carcinoma
Papillary endometrial carcinoma
Mucinous carcinoma
Rarer cancers
Onset at later age
Greater risk for metastases
Poorer prognosis
50% of treatment failure

Spread

Direct spread
Through endometrial cavity to the cervix
Through fallopian tubes to ovary / peritoneum
Invade myometrium reaching serosa
Rare: invasion to pubic bone
Lymphatic spread
Pelvic and para-aortic LN
Inguinal LN ( rare )
Hematogenous spread
Rare but may spread to lungs

Adenocarcinoma uterus

Intraoperatively obtained gross specimen of the uterus, bivalved in a sagittal plane, shows deep invasion (50% of the myometrial thickness) of endometrial carcinoma



Stage 1 Tumour confined to corpus
Stage 1a <50% myometrial invasion
Stage 1b >50% myometrial invasion

Stage 2 Tumour invades Cx stroma


Stage 3 Local/regional tumour spread


3a Invades serosa/+- adnexa
3b Vaginal or parametrial spread
3c1 Positive pelvic nodes
3c2 Positive para-aortic nodes
Stage 4 Invades bladder/bowel/distant

Treatment of endometrial hyperplasia/ carcinoma

Endometrial hyperplasia

Excessive stimulation of the uterine endometrium results in endometrial hyperplasia

Imbalance of hormones or hormonal changes can happen around the time of menopause, and contribute to the development of hyperplasia in some women.

Endometrial hyperplasia of the uterus, by itself, is not cancerous, but requires treatment and monitoring to prevent the risk of cancer.


Managing endometrial hyperplasia

Uterine hyperplasia can get worse, leading to atypical and precancerous cellular changes.

This is why any woman with hyperplasia is considered to be at a higher risk for cancer than one without hyperplasias.

investigate thickened endometrium,
hyperplasia can lead to uterine cancer —
early identification and intervention for uterine abnormalities is highly successful.

The evaluation process begins with a
speculum and bimanual exam
(internal exam and external palpation of the pelvic organs)

An ultrasound and tissue sampling
with endometrial biopsy, hysteroscopy and/or D&C

Hormonal treatment of endometrial hyperplasia

hyperplasia without atypia
progesterone/progestin therapy for three months,
then to retest the endometrium.
Provera
micronized natural progesterone at high doses

Atypia present
option for women who want to wait or avoid surgery altogether is Megace (megestrol acetate), a very potent, orally administered hormonal agent.

Ca Endometrium Treatment Algorithms

Clinical Stage I
TAH BSO

( Grade? Depth? Cell type ?)

Low Risk ~ 75%
Observation

High Risk ~ 25%
EBRT to pelvis
(but~13% have PA nodes)

Treatment of endometrial cancer

Stage II
Consider radical hysterectomy
With macroscopic tumor on cervix:

Consider a cervical cancer

Intra-abdominal spread:
Remove all tumor if possible

Advanced stage

Debulking surgery

Radiotherapy

+/- hormone / chemotherapy

Recurrence

Likely in women with advanced disease
Within 3 years of original diagnosis
Hormone therapy can be considered
External beam pelvic radiation or brachytherapy.